These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 1324552

  • 1. Selectivity and minimal androgenicity of norgestimate in monophasic and triphasic oral contraceptives.
    Anderson FD.
    Acta Obstet Gynecol Scand Suppl; 1992; 156():15-21. PubMed ID: 1324552
    [Abstract] [Full Text] [Related]

  • 2. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive.
    London RS, Chapdelaine A, Upmalis D, Olson W, Smith J.
    Acta Obstet Gynecol Scand Suppl; 1992; 156():9-14. PubMed ID: 1324557
    [Abstract] [Full Text] [Related]

  • 3. A norgestimate-containing oral contraceptive: review of clinical studies.
    Kafrissen ME.
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1196-202. PubMed ID: 1415446
    [Abstract] [Full Text] [Related]

  • 4. A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel.
    Janaud A, Rouffy J, Upmalis D, Dain MP.
    Acta Obstet Gynecol Scand Suppl; 1992 Oct; 156():33-8. PubMed ID: 1324555
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of a monophasic and a triphasic oral contraceptive containing norgestimate.
    Corson SL.
    Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1556-61. PubMed ID: 8178906
    [Abstract] [Full Text] [Related]

  • 6. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins.
    Wiegratz I, Jung-Hoffmann C, Kuhl H.
    Contraception; 1995 Jun; 51(6):341-6. PubMed ID: 7554973
    [Abstract] [Full Text] [Related]

  • 7. Preclinical evaluation of norgestimate, a progestin with minimal androgenic activity.
    Phillips A, Hahn DW, McGuire JL.
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1191-6. PubMed ID: 1415445
    [Abstract] [Full Text] [Related]

  • 8. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters.
    Wiegratz I, Jung-Hoffmann C, Gross W, Kuhl H.
    Contraception; 1998 Aug; 58(2):83-91. PubMed ID: 9773262
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of a new triphasic oral contraceptive in private practice.
    Ellsworth HS, Ayerst RI, Harris JW, Stone RA, Anderson AE, Jones TL, Curtis MK.
    Contraception; 1986 Nov; 34(5):435-42. PubMed ID: 3102161
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and clinical profile of a new oral contraceptive containing norgestimate. U.S. clinical trials.
    Corson SL.
    Acta Obstet Gynecol Scand Suppl; 1990 Nov; 152():25-31. PubMed ID: 2189282
    [Abstract] [Full Text] [Related]

  • 11. Clinical evidence of the minimal androgenic activity of norgestimate.
    Chapdelaine A, Desmarais JL, Derman RJ.
    Int J Fertil; 1989 Nov; 34(5):347-52. PubMed ID: 2571595
    [Abstract] [Full Text] [Related]

  • 12. Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel.
    Gaspard UJ, Buret J, Gillain D, Romus MA, Lambotte R.
    Contraception; 1985 Apr; 31(4):395-408. PubMed ID: 3159546
    [Abstract] [Full Text] [Related]

  • 13. A comparative study of the effects of a monophasic and a triphasic oral contraceptive containing ethinyl estradiol and levonorgestrel on lipid and lipoprotein metabolism.
    Loke DF, Ng CS, Samsioe G, Holck S, Ratnam SS.
    Contraception; 1990 Nov; 42(5):535-54. PubMed ID: 2125546
    [Abstract] [Full Text] [Related]

  • 14. Norgestimate: a clinical overview of a new progestin.
    Bringer J.
    Am J Obstet Gynecol; 1992 Jun; 166(6 Pt 2):1969-77. PubMed ID: 1605287
    [Abstract] [Full Text] [Related]

  • 15. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel.
    Song S, Chen JK, Yang PJ, He ML, Li LM, Fan BC, Rekers H, Fotherby K.
    Contraception; 1992 Jun; 45(6):523-32. PubMed ID: 1535580
    [Abstract] [Full Text] [Related]

  • 16. Effects of three low-dose oral contraceptive formulations on lipid metabolism.
    Bertolini S, Elicio N, Cordera R, Gapitanio GL, Montagna G, Croce S, Saturnino M, Balestreri R, De Cecco L.
    Acta Obstet Gynecol Scand; 1987 Jun; 66(4):327-32. PubMed ID: 2962417
    [Abstract] [Full Text] [Related]

  • 17. Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol and d,l-norgestrel.
    Lemay A, Dewailly SD, Grenier R, Huard J.
    J Clin Endocrinol Metab; 1990 Jul; 71(1):8-14. PubMed ID: 2142494
    [Abstract] [Full Text] [Related]

  • 18. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G, Powell M, Marshall A, Woutersz TB, Steiner G.
    Int J Fertil Menopausal Stud; 1994 Jul; 39(5):283-91. PubMed ID: 7820162
    [Abstract] [Full Text] [Related]

  • 19. Clinical evaluation of a new triphasic oral contraceptive: norgestimate and ethinyl estradiol.
    Gauthier A, Upmalis D, Dain MP.
    Acta Obstet Gynecol Scand Suppl; 1992 Jul; 156():27-32. PubMed ID: 1324554
    [Abstract] [Full Text] [Related]

  • 20. Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel.
    Gaspard UJ, Romus MA, Gillain D, Duvivier J, Demey-Ponsart E, Franchimont P.
    Contraception; 1983 Jun; 27(6):577-90. PubMed ID: 6225622
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.